ScholarLens Back to search
2018•Journal of Thoracic DiseaseOpen access

Neoadjuvant chemoradiotherapy followed by surgery is associated with better survival outcomes in patients with locally advanced esophageal squamous cell carcinoma

Naoya Yoshida, Hideo Baba

Open full text 2 citations

Abstract

Chemoradiotherapy (CRT) is one of the most effective treatments to be expected to cure esophageal cancer of any stage. Esophageal squamous cell carcinoma (ESCC) is more sensitive to CRT than adenocarcinoma. Even in T4 stage ESCC, definitive CRT shows an excellent complete response (CR) rate of up to 52% (1,2). In addition, esophagectomy for ESCC is highly invasive and correlates with frequent postoperative morbidity and mortality. Thus, CRT is widely administered as treatment for ESCC, even when other treatments are considered more appropriate.

Open-access reader

About this research paper

What this paper is about

Chemoradiotherapy (CRT) is one of the most effective treatments to be expected to cure esophageal cancer of any stage. Esophageal squamous cell carcinoma (ESCC) is more sensitive to CRT than adenocarcinoma. Even in T4 stage ESCC, definitive CRT shows an excellent complete response (CR) rate of up to 52% (1,2). In addition, esophagectomy for ESCC is highly invasive and correlates with frequent postoperative morbidity and mortality. Thus, CRT is widely administered as treatment for ESCC, even when other treatments are considered more appropriate.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Chemoradiotherapy (CRT) is one of the most effective treatments to be expected to cure esophageal cancer of any stage. Esophageal squamous cell carcinoma (ESCC) is more sensitive to CRT than adenocarcinoma. Even in T4 stage ESCC, definitive CRT shows an excellent complete response (CR) rate of up to 52% (1,2). In addition, esophagectomy for ESCC is highly invasive and correlates with frequent postoperative morbidity and mortality. Thus, CRT is widely administered as treatment for ESCC, even when other treatments are considered more appropriate.

Key concepts: Medicine, Esophagectomy, Chemoradiotherapy, Esophageal squamous cell carcinoma, Esophageal cancer, Oncology, Stage (stratigraphy), Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Neoadjuvant chemoradiotherapy followed by surgery is associated with better survival outcomes in patients with locally advanced esophageal squamous cell carcinoma — Research Paper | ScholarLens